Literature DB >> 18190631

Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.

Alexandre E Pelzer1, Daniela Colleselli, Jasmin Bektic, Georg Schaefer, Stefano Ongarello, Christian Schwentner, Fritz Aigner, Michael Mitterberger, Eberhard Steiner, Georg Bartsch, Wolfgang Horninger.   

Abstract

OBJECTIVES: To evaluate possible over- and under-diagnosis of prostate cancer in a screened vs a referral population in the same range of prostate-specific antigen (PSA). PATIENTS AND METHODS: In all, 1445 patients undergoing radical prostatectomy and with a PSA level of <10 ng/mL were evaluated; 237 were from outside Tyrol (Austria) and represented the unscreened group, and 1208 were Tyrolean screening volunteers. Over-diagnosis was defined as a pathological stage of pT2a and a Gleason score of <7 with no positive surgical margins. Under-diagnosis was defined as a pathological stage of >or=pT3a or positive surgical margins. The chi-square test was used to assess the differences, with P < 0.05 considered to indicate statistical significance.
RESULTS: There were no significant differences in patient age or PSA levels between the study groups. There was over-diagnosis in the screening and referral groups in 17.4% and 8.9%, respectively, and under-diagnosis in 18.6% and 42.2%, respectively.
CONCLUSION: This study suggests that patients with prostate cancer participating in a screening programme are less likely to be under-diagnosed or have extracapsular disease than their counterparts in a referral population, even in the same PSA range, after radical prostatectomy. Furthermore, there was more under-diagnosis in the referral group than over-diagnosis in the screened group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18190631     DOI: 10.1111/j.1464-410X.2007.07367.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

Review 1.  Overdiagnosis and overtreatment of prostate cancer.

Authors:  Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

2.  Use of screening tests, diagnosis wait times, and wait-related satisfaction in breast and prostate cancer.

Authors:  M Mathews; D Ryan; V Gadag; R West
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

3.  Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.

Authors:  Fritz H Schröder; Marco Zappa
Journal:  Int J Public Health       Date:  2011-11-02       Impact factor: 3.380

4.  Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.

Authors:  Willi Oberaigner; Uwe Siebert; Wolfgang Horninger; Helmut Klocker; Jasmin Bektic; Georg Schäfer; Ferdinand Frauscher; Harald Schennach; Georg Bartsch
Journal:  Int J Public Health       Date:  2011-06-17       Impact factor: 3.380

Review 5.  Overdiagnosis across medical disciplines: a scoping review.

Authors:  Kevin Jenniskens; Joris A H de Groot; Johannes B Reitsma; Karel G M Moons; Lotty Hooft; Christiana A Naaktgeboren
Journal:  BMJ Open       Date:  2017-12-27       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.